Overview

Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation

Status:
Unknown status
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of DA-8031 and to decide the optimal dose of DA-8031 in male patients with premature ejaculation after oral administration on-demand. The investigators hypothesized that newly-developed DA-8031 would effect in delaying ejaculation in patients with premature ejaculation (PE). Design: Placebo-controlled, Randomized, Double-blind, Double-dummy, Parallel group, Fixed dose design
Phase:
Phase 2
Details
Lead Sponsor:
Dong-A Pharmaceutical Co., Ltd.